Colorescience Installs Kiehl's Veteran John Reed as CEO After Roundtable Healthcare Buyout

Colorescience appointed John Reed as chief executive within months of Roundtable Healthcare Partners acquiring the dermatologist-recommended skincare brand earlier in 2025. Reed spent over a decade at Kiehl's, most recently as general manager, where he oversaw North American operations for the L'Oréal-owned heritage apothecary brand. The appointment signals Roundtable's intention to professionalize a brand that has lived primarily in dermatology offices and medical spas rather than department store cosmetics floors.

Colorescience generated an estimated $80 million to $100 million in annual revenue before the acquisition, according to industry observers familiar with the transaction. The brand operates in a specific vertical: mineral-based SPF formulations and color-correcting products sold through roughly 5,000 dermatology practices and medical aesthetics clinics across North America. Roundtable Healthcare Partners, a Boston-based private equity firm managing approximately $4.3 billion, acquired the brand from founder Diane Soltys and earlier investor Water Street Healthcare Partners. Terms were not disclosed.

Reed's tenure at Kiehl's—which grew from approximately $300 million to over $500 million in North American revenue during his leadership—provides a relevant playbook. He managed the brand's expansion from roughly 400 standalone stores and department store counters to a more diversified retail footprint including Sephora, Nordstrom, and digital-first channels. Colorescience now faces a parallel question: how aggressively to expand beyond the dermato-cosmetic channel without alienating the physicians who generate roughly 70 percent of current sales. The brand already maintains a direct-to-consumer website and limited distribution through select medical spas, but has avoided mass prestige retail.

The timing matters for two reasons. First, the medical aesthetics channel is consolidating rapidly. Approximately $8.2 billion in private equity capital moved into dermatology practice roll-ups and medical spa platforms between 2022 and 2024, according to PitchBook data. These platforms increasingly negotiate preferred vendor agreements and volume rebates, shifting power away from individual practitioners. Second, mineral sunscreen regulations in the United States remain in flux. The FDA has not finalized its proposed sunscreen monograph, leaving zinc oxide and titanium dioxide as the only two UV filters with unequivocally "generally recognized as safe" status. Colorescience's entire product line is built around these two actives.

Reed will need to decide whether to defend the professional channel with deeper practice integration—think proprietary in-office diagnostic tools or procedure-specific post-treatment protocols—or push into prestige retail where Supergoop, Tower 28, and Ilia have already established mineral SPF beachheads. The brand's clinical positioning and higher price points—most products range from $52 to $89—suggest room for a hybrid strategy. Worth noting: Kiehl's maintained its apothecary DNA while expanding distribution, but operated under L'Oréal's capital and supply chain infrastructure. Colorescience will need to build that muscle with private equity timeline pressure.

Roundtable Healthcare Partners typically holds portfolio companies for four to seven years and has exited dermatology-adjacent investments including SkinCeuticals distributor Dermstore (sold to Target in 2013) and aesthetic device maker Ulthera (sold to Merz in 2014). The firm's healthcare focus means it understands reimbursement landscapes and physician economics better than generalist consumer private equity, but it also expects 20 percent to 25 percent annual EBITDA growth during the hold period. Reed's first twelve months will likely focus on expanding the sales force covering high-volume dermatology practices and testing limited prestige retail distribution in markets where the brand already has clinical density.

Colorescience will report preliminary 2025 revenue figures in early Q2 2026, which will clarify whether the brand sustained momentum during the ownership transition.